Our review indicates that the EGFR and YAP pathways regulate the tumor immune checkpoint PD-1/PD-L1 in EGFR-mutant NSCLC, and that EGFR-TKIs are appropriate therapy prior to ICIs when sensitive mutations appear. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.